Mereo BioPharma Earnings Estimate

MREO Stock  USD 2.16  0.01  0.47%   
The next projected EPS of Mereo BioPharma is estimated to be -0.0092 with future projections ranging from a low of -0.015 to a high of -0.007. Mereo BioPharma's most recent 12-month trailing earnings per share (EPS TTM) is at -0.34. Please be aware that the consensus of earnings estimates for Mereo BioPharma Group is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
Mereo BioPharma is projected to generate -0.0092 in earnings per share on the 30th of June 2025. Mereo BioPharma earnings estimates show analyst consensus about projected Mereo BioPharma Group EPS (Earning Per Share). It derives the highest and the lowest estimates based on Mereo BioPharma's historical volatility. Many public companies, such as Mereo BioPharma, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Mereo BioPharma's earnings estimates, investors can diagnose different trends across Mereo BioPharma's analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is expected to grow at the current pace this year. In addition to that, Pretax Profit Margin is likely to drop to -3.62Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

Mereo BioPharma Earnings Estimation Breakdown

The calculation of Mereo BioPharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Mereo BioPharma is estimated to be -0.0092 with the future projection ranging from a low of -0.015 to a high of -0.007. Please be aware that this consensus of annual earnings estimates for Mereo BioPharma Group is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.01
-0.01
Lowest
Expected EPS
-0.0092
-0.007
Highest

Mereo BioPharma Earnings Projection Consensus

Suppose the current estimates of Mereo BioPharma's value are higher than the current market price of the Mereo BioPharma stock. In this case, investors may conclude that Mereo BioPharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Mereo BioPharma's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 30th of June 2025Current EPS (TTM)
831.82%
-0.0077
-0.0092
-0.34

Mereo BioPharma Earnings per Share Projection vs Actual

Actual Earning per Share of Mereo BioPharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Mereo BioPharma Group predict the company's earnings will be in the future. The higher the earnings per share of Mereo BioPharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Mereo BioPharma Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Mereo BioPharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Mereo BioPharma should always be considered in relation to other companies to make a more educated investment decision.

Mereo Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Mereo BioPharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-05-23
2025-03-31-0.011-0.0151-0.004137 
2025-03-26
2024-12-31-0.0105-0.00770.002826 
2024-11-12
2024-09-30-0.014-0.0155-0.001510 
2024-09-05
2024-06-30-0.01-0.0862-0.0762762 
null
nullnullnullnull
2023-09-07
2023-06-30-0.02-0.020.0
null
nullnullnullnull
null
nullnullnullnull
2021-06-02
2021-03-31-0.1393-0.13930.0
2021-03-31
2020-12-3100.08420.0842
2020-12-31
2020-09-300-0.2385-0.2385
2020-09-29
2020-06-300-0.225-0.225
2020-06-15
2020-03-31-0.26-3.277-3.0171160 
2020-03-31
2019-12-310-3.2881-3.2881
2019-12-31
2019-09-300-0.5867-0.5867
2019-09-17
2019-06-300-0.5446-0.5446
2019-04-29
2019-03-310-0.6985-0.6985
2019-03-31
2018-12-310-0.7163-0.7163
2018-12-31
2018-09-300-0.6704-0.6704
2018-09-30
2018-06-300-0.6853-0.6853
2018-06-30
2018-03-310-0.7919-0.7919
2018-03-31
2017-12-310-0.8418-0.8418
2017-12-31
2017-09-300-0.7654-0.7654
2017-09-30
2017-06-300-0.7596-0.7596
2017-06-30
2017-03-310-1.1018-1.1018
2017-03-31
2016-12-310-1.0598-1.0598
2016-12-31
2016-09-300-0.651-0.651
2016-09-30
2016-06-300-0.6848-0.6848
2016-06-30
2016-03-310-1.9645-1.9645
2016-03-31
2015-12-310-2.1283-2.1283

About Mereo BioPharma Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Mereo BioPharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Mereo BioPharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Mereo BioPharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-462.9 M-439.7 M
Earnings Yield(0.08)(0.09)
Price Earnings Ratio(11.97)(11.37)
Price Earnings To Growth Ratio 0.12  0.18 

Pair Trading with Mereo BioPharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mereo BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mereo BioPharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Mereo Stock

  0.67GLUE Monte Rosa TherapeuticsPairCorr
  0.65GNLX Genelux CommonPairCorr
The ability to find closely correlated positions to Mereo BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mereo BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mereo BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mereo BioPharma Group to buy it.
The correlation of Mereo BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mereo BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.34)
Revenue Per Share
0.007
Return On Assets
(0.48)
Return On Equity
(0.92)
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.